The 2012 Alzheimer’s Association International Conference (AAIC) Press Release Features REVEAL

The press release entitled, “New Methods Reported for Safely and Accurately Disclosing Alzheimer's Disease Risk based on Newly Approved Tests,” features REVEAL as well as two additional research studies as they aim to understand the effects of disclosing risk information to individuals at imminent risk of Alzheimer’s disease.
07/24/2012

On July 17th, the 2012 Alzheimer's Association International Conference (AAIC), held in Vancouver, British Columbia, Canada, issued a press release describing the creation and evaluation of new risk disclosure methods for Alzheimer’s disease, and the examination of related ethical issues. Since issues around disclosure of dementia risk status are becoming more urgent, many Alzheimer’s prevention trials have developed. The news release entitled, “New Methods Reported for Safely and Accurately Disclosing Alzheimer's Disease Risk based on Newly Approved Tests,” features REVEAL as well as two additional research studies as they aim to understand the effects of disclosing risk information to individuals at imminent risk of Alzheimer’s disease.

According to Robert C. Green, M.D., M.P.H., the REVEAL study is the first study to examine the impact of disclosing Alzheimer's genetic risk information to individuals with Mild Cognitive Impairment (MCI). He states that, "through REVEAL, we hope to learn how people with MCI and their study partners respond to health education and learning risk information." Dr. J. Scott Roberts, Ph.D., who is chair of an AAIC 2012 featured research session where new research on disclosing risk information will be reported and discussed, comments on the use of biomarkers by stating, “biomarkers are being increasingly used in clinical practice and research trials to provide risk information for Alzheimer's. The goal is to develop evidence-based methods for communicating this risk in effective and supportive ways.”

To view the full press release, please click here.